FDA Accepts Nuvalent's Neladalkib NDA with Priority Review; Positive Pivotal Data for Two Oncology Assets
NUVL sits 53% above its 52-week low of $70.25.
Summary
The FDA has accepted Nuvalent's New Drug Application for neladalkib, granting it Priority Review with a PDUFA action date of November 27, 2026. This follows the company's NDA submission in April and prior news of the acceptance. Crucially, Nuvalent also reported positive pivotal data for both neladalkib (ALK+) and zidesamtinib (ROS1+), significantly de-risking its oncology pipeline. The company plans 2026 commercial launches for these assets, supported by its strong cash position. The PDUFA date for neladalkib is November 27, 2026.
At the time of this announcement, NUVL was trading at $107.38 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $8.5B. The 52-week trading range was $70.25 to $113.02. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: Wiseek News.